Paoletti A M, Cagnacci A, Depau G F, Orrù M, Ajossa S, Melis G B
Istituto di Ginecologia Ostetricia e Fisiopatologia della Riproduzione Umana, Università degli Studi di Cagliari, Italy.
Fertil Steril. 1996 Oct;66(4):527-32. doi: 10.1016/s0015-0282(16)58563-x.
To investigate whether the administration of the long-lasting dopaminergic drug, cabergoline, improves endocrine and clinical features of women with polycystic ovary syndrome (PCOS).
Twenty-nine women participated in the study: 14 women with clinical and endocrinologic features of PCOS and 15 age- and weight-matched normal cycling women. Each subject was assigned randomly to receive either a tablet of cabergoline at the dose of 0.5 mg/wk or placebo for 4 months. Sixteen subjects (PCOS: n = 8; controls: n = 8) received cabergoline, whereas 13 (PCOS: n = 6; controls: n = 7) received placebo.
Both before and during the 4th month of treatment, blood samples were collected every 10 minutes from 9:00 A.M. to 3:00 P.M., 3 to 7 days after spontaneous or medroxy-progesterone acetate (MPA; 5 mg daily for 5 days)-induced menses. Follicle-stimulating hormone and androgen levels were measured in the basal samples, whereas LH levels were measured in all samples.
Menstrual cyclicity, LH pulsatility, and circulating levels of FSH, PRL, E2, total T, free T, androstenedione, 17 alpha-hydroxyprogesterone, DHEAS, and sex hormone-binding globulin.
Both in controls and in PCOS-affected women, cabergoline administration blunted plasma PRL levels without affecting LH pulsatility. Androgen levels were reduced in controls and normalized in PCOS. Cabergoline, but not placebo, induced menses reappearance in amenorrheic and a normalization of menstrual cyclicity in oligoamenorrheic women with PCOS.
The administration of cabergoline is capable to normalize androgen levels and to improve menstrual cyclicity in PCOS-affected women. Cabergoline may represent an useful treatment for menstrual irregularities of PCOS patients.
研究长效多巴胺能药物卡麦角林的给药是否能改善多囊卵巢综合征（PCOS）女性的内分泌及临床特征。
29名女性参与了该研究，其中14名具有PCOS临床和内分泌特征，15名年龄及体重匹配的正常月经周期女性。每位受试者被随机分配接受每周0.5毫克剂量的卡麦角林片剂或安慰剂，为期4个月。16名受试者（PCOS组：n = 8；对照组：n = 8）接受卡麦角林，而13名（PCOS组：n = 6；对照组：n = 7）接受安慰剂。
在治疗的第4个月之前及期间，于自然月经或醋酸甲羟孕酮（MPA；每日5毫克，共5天）诱导月经后3至7天，从上午9:00至下午3:00每10分钟采集一次血样。基础样本中测量促卵泡生成素和雄激素水平，所有样本中测量促黄体生成素水平。
月经周期、促黄体生成素脉冲性以及促卵泡生成素、催乳素、雌二醇、总睾酮、游离睾酮、雄烯二酮、17α-羟孕酮、硫酸脱氢表雄酮和性激素结合球蛋白的循环水平。
在对照组和PCOS患者中，卡麦角林给药均使血浆催乳素水平降低，而不影响促黄体生成素脉冲性。对照组雄激素水平降低，PCOS患者雄激素水平恢复正常。卡麦角林而非安慰剂使PCOS闭经女性月经重现，使PCOS月经过少女性月经周期恢复正常。
卡麦角林给药能够使PCOS患者雄激素水平正常化并改善月经周期。卡麦角林可能是治疗PCOS患者月经不调的有效药物。
